Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	$ (3,456)	$ (2,598)	$ (6,912)	$ (4,378)
Royalty revenue	10,434	663	17,108	(387)
Revenue from Collaborative Arrangements	221	271	443	541
Total revenue	10,655	934	$ 17,551	154
Theravance Biopharma | Common Stock
Information related to collaborative arrangements
Number of ordinary shares sold			436,802
GSK
Information related to collaborative arrangements
Royalties from a related party	13,890	3,261	$ 24,020	3,991
Less: amortization of capitalized fees paid to a related party	(3,456)	(2,598)	(6,912)	(4,378)
Royalty revenue	10,434	663	17,108	(387)
Total revenue	10,655	934	17,551	154
GSK | MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	363,000		363,000
Long-acting beta agonist (LABA) collaboration | GSK
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	(3,500)	(2,600)	$ (6,900)	(4,400)
Obligation for milestone payments					$ 220,000
Royalty rate for first level of annual global net sales (as a percent)			15.00%
Annual global sales level used to determine royalty rate			$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)			5.00%
Long-acting beta agonist (LABA) collaboration | GSK | Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)			6.50%
Long-acting beta agonist (LABA) collaboration | GSK | Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)			10.00%
2004 Strategic alliance | GSK | MABA
Information related to collaborative arrangements
Revenue from Collaborative Arrangements	$ 221	$ 271	$ 443	$ 541